Teriparatide is a recombinant parathyroid hormone (PTH) analog and a potent osteoanabolic agent. It is made up of the first amino(N)-terminal 34 amino acids of the human PTH. First approved in the United States in November 2002 and in Europe in April 2003, teriparatide makes the first approved drug in a new category of osteoporosis therapy called anabolic th...
Teriparatide is indicated:
Brigham and Women's Hospital, Boston, Massachusetts, United States
Saint-Petersburg State University Hospital, Saint Petersburg, Russian Federation
Istituto Ortopedico Galeazzi IRCCS, Milano, Italy
Fort Jackson, Columbia, South Carolina, United States
Aalborg University Hospital, Aalborg, Denmark
Steno Diabetes Center Copenhagen, Gentofte, Denmark
Herlev and Gentofte Hospital, Herlev Hospital, Herlev, Denmark
424 General Military Hospital, Thessaloniki, Northern Greece, Greece
Darlington Memorial Hospital, Darlington, County Durham, United Kingdom
Massachusetts General Hospital, Boston, Massachusetts, United States
Jason Pui Yin Cheung, Hong Kong, Please select an option below, Hong Kong
Duchess of Kent Children's Hospital, Hong Kong, Hong Kong
Queen Mary Hospital, Hong Kong, Hong Kong
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.